Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
Joseph Walter Vazzano, identified as the company's Chief Financial Officer, reported a sale of 15,000 shares of Abeona Therapeutics Inc. (ABEO) on 08/15/2025. The shares were sold at a weighted-average price of $7.3572, with transaction prices ranging from $7.20 to $7.48. After the sale, Vazzano beneficially owned 462,666 shares. The Form 4 was filed by a single reporting person and is signed by Vazzano on the transaction date.
Abeona Therapeutics (ABEO) Form 144: This notice shows an intended sale of 15,000 shares of common stock through Stifel Nicolaus with an aggregate market value of $110,358, scheduled approximately for 08/15/2025. The filer acquired 47,303 shares as restricted stock units on 06/05/2024 and indicates cash payment on 06/06/2025. Recent disclosed sales by the same person total 64,708 shares for gross proceeds of $278,087.63 across trades on 06/06/2025, 07/09/2025, and 07/22/2025.
The form is a routine Section 144 notice required for proposed sales by an affiliate and includes the filer’s representation that no undisclosed material adverse information is known. The shares to be sold represent a small fraction of the issuer’s reported 51,278,539 outstanding shares.
Abeona Therapeutics reported a materially different quarter driven by regulatory and one-time transaction events. The FDA approved ZEVASKYN on April 28, 2025, and the company recognized a $152.4 million gain from the sale of a Priority Review Voucher, producing net income of $108.8 million for the three months ended June 30, 2025 and $96.8 million for the six months ended June 30, 2025. Cash and cash equivalents rose to $163.5 million and short-term investments were $62.0 million, increasing total assets to $246.2 million and stockholders' equity to $163.6 million as of June 30, 2025.
Operationally the company remains a commercial-stage biopharmaceutical developer of cell and gene therapies: license revenues were modest ($0.4 million) and the six-month loss from operations before the PRV gain was $42.5 million. Debt principal under the Loan Agreement remains $20.0 million with current maturities of $5.6 million and a covenant to maintain $5.0 million in unrestricted cash. Warrant liabilities totaled $30.2 million. Management states available capital resources are sufficient to fund operations for at least the next 12 months.
Abeona Therapeutics, Inc. filed a Current Report on Form 8-K stating that on August 14, 2025 it issued a press release reporting its financial results for the quarter ended June 30, 2025. The press release is filed as Exhibit 99.1 to the report and a Cover Page Interactive Data File is included as Exhibit 104. The 8-K specifies that the press release and related information are incorporated as exhibits but are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference in other filings except by specific reference. The report is signed by CFO Joseph Vazzano.
A Schedule 13G/A reports that Suvretta Capital Management, LLC and Aaron Cowen each disclose beneficial ownership of 2,676,000 shares of Abeona Therapeutics common stock, representing 5.2% of the class, while Averill Master Fund, Ltd. holds 2,309,267 shares ( 4.5% ). Each reporting person shows zero sole voting or dispositive power and reports the corresponding amounts as shared voting and dispositive power. The filers state the securities are directly owned by advisory clients of Suvretta and that the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.